About Mammoth Biosciences
Mammoth Biosciences focuses on molecular diagnostics using CRISPR technology to develop tests that quickly and accurately identify ailments, including infectious diseases like COVID-19, at the point of care. This allows for immediate results, reducing delays associated with traditional lab tests. The company differentiates itself with its versatile CRISPR-based detection platform, which offers a wide range of testing applications. Mammoth's goal is to enhance the accessibility and efficiency of diagnostic testing in response to global health challenges.
Brisbane, CaliforniaHeadquarters
2017Year Founded
$353.3MTotal Funding
LATE_VCCompany Stage
Biotechnology, HealthcareIndustries
51-200Employees
Benefits
Medical, dental, & vision
401(k)
Unlimited vacation
Transportation subsidy
Onsite amenities
Happy hours
Risks
Emerging competition from companies like VedaBio challenges market position.
Recent layoffs may indicate internal challenges or strategic shifts.
Regulatory hurdles could delay market entry for gene-editing therapies.
Differentiation
Mammoth Biosciences leverages novel CRISPR systems like Cas12, Cas13, and Cas14.
Co-founded by CRISPR pioneer Jennifer Doudna, enhancing credibility and innovation.
Focuses on democratizing disease detection with affordable, real-time point-of-care tests.
Upsides
Collaboration with Regeneron enhances CRISPR-based gene-editing capabilities.
$95 million investment from Regeneron boosts financial resources for CRISPR advancements.
Presentation at ASGCT highlights progress in ultracompact CRISPR systems for genetic diseases.
Funding
Total raised$353.31 M
Latest valuation$1.00 B
StageLATE_VC
LATE VC
3/31/2024$100
$1.00 BSERIES C
10/31/2020$45
$225.00 MSERIES B
12/31/2019$45
$225.00 MSERIES A
6/30/2018$23
$115.00 MGRANT
9/30/2017N/A
SEED
4/30/2017N/A
$600.0 K